Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Licensing Trial Drugs To Foreign Firms A Failure For Indian Pharmas

This article was originally published in PharmAsia News

Executive Summary

The practice of Indian drug makers of licensing to foreign companies some of the molecules they have in clinical trials has not been a successful one for the licensing firms. Many of the licensed molecules have failed to survive late-stage trials, with a result of the foreign licensees simply abandoning them. Facing a shortage of finances necessary to carry on the work themselves, major Indian pharmas today focus on secondary research activities such as new delivery systems. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts